🎁 Black Friday: up to 50% off of annual plans
Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
41.37
-2.28 (-5.22%)
At close: Nov 20, 2026, 4:00 PM EST
41.40
+0.03 (0.07%)
After-hours: Nov 20, 2026, 7:30 PM EST

Arrowhead Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Arrowhead Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $105.86. The average 1-year stock price forecast is 155.89% higher than the current stock price, while the lowest is $73 (+76.46%) and the highest is $126 (+204.57%).

Price Target: $105.86 (+155.89%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$73$105.86$105$126
Change+76.46%+155.89%+153.81%+204.57%

Analyst Ratings

The average analyst rating for Arrowhead Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy78891010
Buy444444
Hold200111
Sell000000
Strong Sell000000
Total131212141515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Citi
Citi
Buy
Maintains
$108 → $105
BuyMaintains$108 → $105+153.81%Nov 17, 2026
Bank of America Securities
Bank of America Securities
Buy
Maintains
n/a
BuyMaintainsn/an/aNov 13, 2026
RBC Capital
RBC Capital
Buy
Reiterates
$100
BuyReiterates$100+141.72%Nov 13, 2026
Morgan Stanley
Morgan Stanley
Buy
Maintains
$120 → $106
BuyMaintains$120 → $106+156.22%Nov 13, 2026
Unknown Analyst
UBS
No rating
UBS
Buy
Reiterates
$109
BuyReiterates$109+163.48%Nov 13, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
312.04M
from 450.82M
Decreased by -30.78%
Revenue Next Year
532.25M
from 312.04M
Increased by 70.57%
EPS This Year
-5.79
from -3.61
EPS Next Year
-4.03
from -5.79
Fiscal YearFY 2022FY 2023FY 2024FY 2025FY 2026FY 2027E
Period EndingSep 30, 2022Sep 30, 2023Sep 30, 2024Sep 30, 2025Sep 30, 2026Sep 30, 2027
Revenue
243.23M240.74M3.55M829.45M450.82M312.04M
Revenue Growth
75.89%-1.03%-98.53%23,258.15%-45.65%-30.78%
Gross Profit
243.23M240.74M3.55M829.45M449.02M298.44M
Gross Margin
100.00%100.00%100.00%100.00%99.60%95.64%
Operating Income
-178.51M-205.00M-601.08M98.35M-707.17M-740.18M
Net Income
-176.06M-205.28M-599.49M-1.63M-724.21M-760.59M
EPS
-----3.61-5.79
Free Cash Flow
------552.90M
No. Analysts
-----16
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202720282029
High820.0M
Avg312.0M
Low122.0M

Revenue Growth

Revenue Growth202720282029
High
81.9%
Avg
-30.8%
Low
-72.9%

EPS Forecast

EPS202720282029
High-3.91
Avg-5.79
Low-8.16

EPS Growth

EPS Growth202720282029
High-
Avg-
Low-